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cancer in relation to resection 
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It is unclear whether gastrectomy or oesophagectomy offer better outcomes for gastro-oesophageal 
junction (GOJ) cancer. A total of 240 patients undergoing total gastrectomy (n = 85) or oesophagectomy 
(n = 155) for Siewert II-III GOJ adenocarcinoma were identified from a Swedish prospective population-
based nationwide cohort. The surgical approaches were compared in relation to non-radical resection 
margins (main outcome) using multivariable logistic regression, providing odds ratios (ORs) and 
95% confidence intervals (CIs), mean number of removed lymph nodes with standard deviation (SD) 
using ANCOVA, assessing mean differences and 95% CIs, and 5-year mortality using Cox regression 
estimating hazard ratios (HRs) and 95% CIs. The models were adjusted for age, sex, comorbidity, 
tumour stage, and surgeon volume. The non-radical resection rate was 15% for gastrectomy and 14% 
for oesophagectomy, and the adjusted OR was 1.61 (95% CI 0.68–3.83). The mean number of lymph 
nodes removed was 14.2 (SD ± 9.6) for gastrectomy and 14.2 (SD ± 10.4) for oesophagectomy, with 
adjusted mean difference of 2.4 (95% CI-0.2–5.0). The 5-year mortality was 76% following gastrectomy 
and 75% following oesophagectomy, with adjusted HR = 1.07 (95% CI 0.78–1.47). Gastrectomy and 
oesophagectomy for Siewert II or III GOJ cancer seem comparable regarding tumour-free resection 
margins, lymph nodes removal, and 5-year survival.
The curative treatment of adenocarcinoma of the gastro-oesophageal junction (GOJ) typically includes surgical 
resection. Multimodality treatment and centralization of surgery has improved the 5-year survival rates1,2, but 
there is an on-going debate about the optimal surgical approach for GOJ cancer3. GOJ cancers of Siewert type 
I are managed by oesophagectomy, but there is variation in the approach for Siewert type II or III tumours, 
although oesophagectomy is overrepresented in Siewert type II cancer and total gastrectomy is often preferred 
in Siewert type III cancer4. Additionally, the exact origin of GOJ tumours can sometimes be difficult to accu-
rately assess, particularly in large and bulky tumours, which can make the choice between oesophagectomy 
and gastrectomy arbitrary5. Non-radical resection margins (with cancer involvement) have a profound nega-
tive effect on GOJ cancer survival1. Studies have shown contradictory results regarding radical (R0) resection 
rates between gastrectomy and oesophagectomy. Some studies have found no difference between the approaches, 
while others have shown favourable results for either gastrectomy or oesophagectomy6–13. Some research has 
shown a survival benefit associated with more extensive lymphadenectomy for oesophageal and GOJ cancer14,15, 
while more recent studies have questioned such a benefit after adjustment for confounding, including surgeon 
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volume16,17. Nevertheless, the number of removed lymph nodes during surgery is often considered an indicator of 
the radicality and quality of the surgery. Gastrectomy and oesophagectomy seem to be associated with a similar 
prognosis7,18,19, but uncertainty remains due to the limited number of studies specifically evaluating GOJ cancer. 
Therefore, we aimed to compare gastrectomy with oesophagectomy in relation to the outcomes radicality of the 
resection margins, lymph node yield, and survival in patients with GOJ cancer of Siewert type II or III (where 
gastrectomy and oesophagectomy are alternative surgical approaches), in an unselected cohort study with adjust-
ment for potential confounders.
Methods
Study design and data sources. The design of this nationwide Swedish, population-based and prospective 
cohort study has been described in detail elsewhere20. In brief, 90% of all patients who underwent surgery for 
oesophageal or GOJ cancer in Sweden during the period April 2, 2001 to December 31, 2005 were included. These 
patients were followed up until February 2016, i.e. we had 5-year follow-up of all patients. Among all 616 patients 
enrolled in the source cohort, this study included 240 patients who had undergone gastrectomy or oesophagec-
tomy with curative intent for local or locally advanced Siewert type II or III GOJ adenocarcinoma. Siewert II or 
III tumour was defined based on the postoperative pathology reports as an adenocarcinoma with its epicentre up 
to 1 cm above or up to 5 cm below the GOJ, measured from the proximal margin of the gastric folds21. For some 
patients with type II or III the exact Siewert classification could not be reliably determined based on the pathology 
reports, and these patients were further grouped as unclear type II or III GOJ cancers. In 2001–2005, neoadjuvant 
or adjuvant therapy was rarely used in Sweden, which makes this an almost exclusively surgical cohort rather than 
a multimodality therapy cohort. Information regarding patient and tumour characteristics and surgical details 
was prospectively collected from all relevant hospitals in Sweden. Tumour staging was based on the postoperative 
stage defined by the pathologist according to the 6th edition of TNM-classification, which is uniform regarding 
Siewert II and III tumours and was used during the time of the data collection22. Data on comorbidities were 
obtained from the Swedish Patient Registry, using the most recent and well-validated version of the Charlson 
Comorbidity Index23. The mortality data were retrieved from the Swedish Causes of Death Registry. The study 
was approved by the Regional Ethical Review Board in Stockholm, Sweden. All methods were carried out in 
accordance with relevant guidelines and regulations. All participating patients gave informed consent.
Exposures. The surgical approach was decided mainly based on the experience of the operating surgeon. The 
study exposure was either of two surgical approaches:
 1) Gastrectomy: Total gastrectomy including resection of the distal oesophagus through laparotomy and 
anastomosis above the diaphragm. Reconstruction was achieved most commonly using the Roux-en-Y 
method.
 2) Oesophagectomy: Resection of most parts of the oesophagus and the proximal stomach through laparoto-
my and thoracotomy, with a gastric pull-up reconstruction and an anastomosis in the upper chest in over 
95% of the cases.
No consensus regarding the extent of lymphadenectomy existed during the study period, but moderately 
extensive lymphadenectomies were preferred.
Outcomes. The primary outcome of the study was tumour involvement of the resection margins: Growth of 
tumour cells at the cut margin of resection seen under the microscope (R1) or residual tumour that could not be 
resected during surgery, as reported by the surgeon (R2).
The secondary outcomes of the study were 1) Lymph node yield: The number of lymph nodes removed and 
identified by the pathologist after the resection; and 2) mortality: The 5-year all-cause mortality, counted from 
the date of surgery. The crude 5-year mortality analysis has been reported as a secondary outcome of a previous 
study from this cohort24.
Statistical analysis. Different statistical methods were used for each of the three outcomes under 
investigation.
 1) Multivariable logistic regression was used to evaluate the risk of non-radical resection margins. The risk 
estimates were odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for the following potential 
confounding variables: age (categorized into <65 years, 65–75 years, or >75 years), sex (male or female), 
comorbidity (Charlson’s Comorbidity Index23,25 score 0, 1 or ≥2), pathological tumour stage (0-I, II, or III-
IV), and surgeon volume (0–3, 4–10, or ≥11 operations during the study period).
 2) ANCOVA was used to assess the mean lymph node yield as a continuous variable and to adjust for all con-
founding factors (with the same categorizations) listed above. The results were presented as mean number 
of lymph nodes with standard deviation (SD), and mean difference ± SD.
 3) Cox proportional hazards model was used to calculate the risk of 5-year mortality. The risk estimates were 
hazard ratios (HRs) with 95% CIs, adjusted for all confounding factors (with the same categorizations) 
listed above.
The oesophagectomy group was the reference category in all analyses.
The data management and statistical analyses were conducted by a senior biostatistician (KW), who followed 
the analysis plan decided in a detailed and pre-defined study protocol. The statistical software IBM SPSS v24.0 
(IBM Corp., Armonk, NY) was used for all statistical analyses.
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Results
Patients. Among all 240 patients with GOJ cancer included in this study, 159 (66%) had Siewert type II can-
cer, 67 (28%) had Siewert type III cancer and 13 (6%) patients had a type II or III cancer that could not be reliably 
determined as either. Of these participating patients, 85 (35%) underwent gastrectomy and 155 (65%) underwent 
oesophagectomy. Patients who underwent gastrectomy were slightly older, had more comorbidity, were more 
likely to have Siewert type III cancer, low histological grade of differentiation and were less likely to be operated 
on by high-volume surgeons, while the sex and tumour stage distribution were similar between the comparison 
groups (Table 1).
Resection margins. The proportion of patients who had non-radical resection was similar when compar-
ing gastrectomy (15%) and oesophagectomy (14%). The adjusted OR was not statistically significantly increased 
when comparing gastrectomy with oesophagectomy (OR 1.61, 95% CI 0.68–3.83) (Table 2).
Lymph node yield. The mean number of lymph nodes was similar in the gastrectomy (14.2 nodes, SD ± 9.6) 
and oesophagectomy (14.2 nodes, SD ± 10.4) groups (p = 0.996) (Table 3). In the adjusted analysis, the number of 
removed lymph nodes was not statistically increased in the gastrectomy group versus the oesophagectomy group 
(mean difference 2.4, 95% CI-0.2–5.0).
Oesophagectomy Gastrectomy Total
Number (%) Number (%) Number (%)
Total 155 (100) 85 (100) 240 (100)
Age (in years)
   <65 66 (42) 27 (32) 93 (39)
   65–75 58 (37) 32 (38) 90 (38)
   >75 31 (20) 25 (31) 57 (24)
Sex
   Male 128 (83) 69 (81) 230 (82)
   Female 27 (17) 16 (19) 52 (18)
Charlson’s Comorbidity Index
   0 83 (54) 42 (49) 125 (52)
   1 40 (26) 17 (20) 57 (24)
   ≥2 32 (21) 26 (31) 58 (24)
Siewert type
   II 122 (79) 37 (44) 159 (66)
   III 20 (13) 47 (56) 67 (28)
   Unclear II or III 13 (8) 1 (1) 14 (6)
Histological grade of differentiation
   Well differentiated 5 (6) 10 (7) 15 (6)
   Moderately differentiated 26 (31) 63 (41) 89 (37)
   Poorly differentiated 51 (60) 71 (46) 122 (51)
   Unknown 3 (4) 11 (7) 14 (6)
Tumour stage
   0-I 29 (19) 19 (22) 48 (20)
   II 38 (25) 27 (32) 65 (27)
   III-IV 83 (54) 39 (46) 122 (51)
   Missing 5 (3) 0 (0) 5 (2)
Surgeon volume
   Low (≤3) 52 (34) 33 (39) 85 (35)
   Mid (4–10) 45 (29) 39 (46) 84 (35)
   High (≥11) 58 (37) 13 (15) 71 (30)
Resection margins
   R0 134 (87) 72 (85) 206 (86)
   R1/R2 21 (14) 13 (15) 34 (14)
Number of removed lymph nodes
   ≤9 56 (36) 31 (36) 87 (36)
   10–17 49 (32) 25 (29) 74 (31)
   ≥18 47 (30) 25 (29) 72 (30)
   Missing 3 (2) 4 (5) 7 (3)
Table 1. Patient and surgical characteristics of the 240 patients who underwent oesophagectomy or gastrectomy 
for gastro-oesophageal junction adenocarcinoma of Siewert type II or III.
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Mortality. No difference was observed in the absolute 5-year mortality between the gastrectomy (77%) and 
oesophagectomy (76%) groups. The adjusted HR of all-cause 5-year mortality was 1.07 (95% CI 0.78–1.47) when 
comparing gastrectomy with oesophagectomy (Table 4).
Discussion
This study indicates that gastrectomy and oesophagectomy produce similar outcomes regarding non-radical 
resection margins, lymph node yield, and 5-year prognosis for Siewert II and III GOJ cancer.
An advantage of this study is the population-based cohort design with coverage of more than 90% of GOJ 
cancer patients undergoing surgery in Sweden during the study period, providing an unselected cohort. Another 
strength is the strict inclusion of only Siewert type II and III tumours, where both gastrectomy and oesophagec-
tomy may be used. The prospective data collection and centralized review of these data provided accurate and 
unbiased information about exposures, outcomes, and confounders. The study followed a detailed study protocol, 
with all definitions, categorizations, and analyses decided on beforehand. Additionally, the results were adjusted 
for a number of potential confounders, including surgeon volume26. The study period is not very recent, which 
might be seen as a limitation. However, this made it possible to examine a surgical cohort, almost without influ-
ence of neoadjuvant therapy (only 2% in this study), while only more recently the use of neoadjuvant therapy has 
become standard care. Neoadjuvant therapy could otherwise confound the assessment of surgical approach in 
relation to all study outcomes in this study. Despite the nationwide assessment of cases, a weakness is the limited 
sample size followed by the selection of Siewert type II and III tumours. In Sweden the incidence of GOJ cancers 
is relatively low27 and only a small proportion of these patients undergo resection28. Yet, this is one of the largest 
studies comparing gastrectomy and oesophagectomy in relation to resection margins and the extent of lymphad-
enectomy in Siewert II-III GOJ cancers. Finally, another potential limitation is residual confounding due to fac-
tors that we grouped or did not take into account, such as tumour recurrences. However, tumor recurrence data 
were not available for this study, and we adjusted for all other factors that were considered potential confounders.
This study showed no major difference in the radical resection rates for GOJ in cancer between gastrectomy 
and oesophagectomy. Only one population-based study and a few single-centre studies have compared rates of 
radical resection margin between these two approaches in GOJ cancers. Four of these studies support the results 
of the present study, and the R0 resection rates in this study (85%-86%) are well in line with other previous 
studies showing R0 resection rates between 72%–93% for oesophagectomy or gastrectomy for GOJ cancer7,10. 
A recent large (n = 1196) population-based Dutch study implied similar radical (R0) resection rates between 
gastrectomy (84%) and oesophagectomy (87%)10. However, this study had a high proportion (41%) of missing T 
stage data for patients who underwent gastrectomy, and was potentially confounded by the use of neoadjuvant 
therapy. A single-institution US study of 505 patients with GOJ cancers (393 with Siewert II-III cancer) found no 
differences in resection margin status between gastrectomy and oesophagectomy6. However, surgical treatment 
evolved during the long duration of that study (1985–2003), for example, 138 of 153 patients in the gastrectomy 
Model
Surgical approach
Oesophagectomy n = 155 Gastrectomy n = 85
Crude OR (95% CI) 1 (reference) 1.15 (0.55–2.44)
Adjusted OR (95% CI)† 1 (reference) 1.61 (0.68–3.83)
Table 2. Logistic regression analysis of the risk of non-radical resection margin status presented as odds ratios 
(ORs) and 95% confidence intervals (CIs). †Adjusted for: age, sex, comorbidities, tumour stage and surgeon 
volume. Five patients excluded from the oesophagectomy group because of missing tumour stage.
Surgical approach
Oesophagectomy n = 152 Gastrectomy n = 81
Mean (95% CI) 14.2 (12.6–15.8) 14.2 (12.0–16.4)
Adjusted mean (95% CI)† 12.7 (10.8–14.7) 15.1 (12.7–17.5)
Table 3. Analysis of covariance (ANCOVA) on the number of lymph nodes removed and surgical approach, 
presented as means with 95% confidence intervals (CIs). †Adjusted for: age, sex, comorbidities, tumour stage 
and surgeon volume. Four patients excluded from the oesophagectomy group because of missing tumour stage.
Surgical approach
Oesophagectomy n = 155 Gastrectomy n = 85
Crude HR (95% CI) 1 (reference) 1.04 (0.77–1.41)
Adjusted HR (95% CI)† 1 (reference) 1.07 (0.78–1.47)
Table 4. Cox proportional-hazards regression analysis of 5-year mortality and surgical approach, presented as 
hazard ratios (HRs) and 95% confidence intervals (CIs). †Adjusted for: age, sex, comorbidities, tumour stage 
and surgeon volume. Five patients excluded from the oesophagectomy group because of missing tumour stage.
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group underwent proximal gastrectomy, which is no longer used in cancer surgery. A single-centre study from 
Sweden (n = 143) also suggested similar R0 resection rates for the surgical approaches under study8. Finally, a 
prospective study from Germany examining Siewert II cancer (n = 92) indicated that R0 resection rates were sim-
ilar between gastrectomy and oesophagectomy13. Some studies are in disagreement with the results of the present 
investigation. A retrospective French study implied a favourable rate of R0 resection with gastrectomy versus 
oesophagectomy in Siewert I-III GOJ cancer (n = 126)11. On the other hand, a retrospective US study found 
favourable results with oesophagectomy compared to gastrectomy in Siewert type II-III GOJ cancer (n = 82)9. 
Additionally, a prospective Dutch study suggested an increased rate of positive circumferential resection mar-
gins associated with gastrectomy in Siewert II patients (n = 176)12. Unfortunately, none of these previous studies 
adjusted their results for tumour stage or surgeon volume. Additionally, the debate of whether to advocate gas-
trectomy or oesophagectomy is related to Siewert II-III GOJ cancers rather than Siewert I GOJ cancer, for which 
oesophagectomy is clearly preferred. Inclusion of Siewert I GOJ cancers in some of these aforementioned studies 
might have produced results that are biased towards favouring oesophagectomy. Taken together, the results of 
these studies suggest that both gastrectomy and oesophagectomy can be applied to Siewert II-III GOJ cancers 
from the perspective of tumour-free resection margins.
The present study found similar lymph node yield when comparing gastrectomy and oesophagectomy, which 
remained after adjustment for surgeon volume and other potential confounding factors. The mean number of 
lymph nodes removed differ from study to study comparing gastrectomy and oesophagectomy for GOJ can-
cer, highlighting the differences between institutional treatment regimens6,9,13. In the present study, the mean 
lymph node yield was relatively small with higher variability than other studies on the topic, reflecting the lack 
of national consensus on the extent of lymphadenectomy in GOJ cancer, as well as the preference for limited 
lymphadenectomy among upper gastrointestinal surgeons in Sweden. However, five studies, two from the United 
States6,9, one from Germany13, and two from the Netherlands10,12, found no differences in lymph node yield 
between gastrectomy and oesophagectomy, which corroborate the findings of the present study. However, sur-
geon experience has been shown to influence the number of resected lymph nodes during surgery with increasing 
lymph node counts by increasing surgeon volume26, but was adjusted for only in the present study. Nevertheless, 
taking the results from previous studies and this study into account, gastrectomy and oesophagectomy seem to 
allow for a similar number of lymph nodes to be removed.
The 5-year all-cause mortality rate observed in this study were similar between the surgical approaches, which 
is well in line with the results from most previous research on this topic9–11,19,29. Taken together, there might not be 
survival difference between gastrectomy and oesophagectomy in Siewert II and III GOJ cancers, or any difference 
is likely to be small. As there were no data available on the recurrences in this cohort, it would be interesting to 
compare the recurrence rates between these approaches, or to conduct analysis by adjusting for the treatment of 
the recurrences in a larger study.
There are clinical implications to the findings of this study. The results indicate that gastrectomy and 
oesophagectomy are equally good at achieving complete resection of the tumour and adequate lymphadenec-
tomy without compromising survival in Siewert II and III GOJ cancers, ultimately supporting whichever surgical 
approach is preferred by the individual surgeon. However, the results also highlight that patient-reported out-
comes might be of great relevance in future research comparing gastrectomy and oesophagectomy. Gastrectomy 
might, for example, reduce the risk of pulmonary complications, which are known to influence the patients’ 
health-related quality of life in the long term30, while gastrectomy might be associated with more nutritional 
problems.
In conclusion, this population-based cohort study with adjustment for potentially important confounding 
factors indicates that total gastrectomy and sub-total oesophagectomy provide similar rates of radical resection 
margins, number of lymph nodes removed, and 5-year all-cause mortality for Siewert II or III GOJ cancer. The 
surgical approach for Siewert II and III cancers could be chosen on the basis of experience of the surgeon, but 
gastrectomy might be preferable to avoid thoracotomy-related complications.
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